JAJamshid Ahmadi

Jamshid Ahmadi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jamshid Ahmadi has a total of 170 co-authors. Here are the top co-authors by number of shared publications:

  • Saxby Pridmore

    University of Tasmania

    15 shared publications
  • Leila Benrazavi

    Shiraz University of Medical Sciences , Shiraz, Iran

    5 shared publications
  • Ahmad Ghanizadeh

    Professor, Director, Substance Abuse Research Center AND Department of Psychiatry, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

    4 shared publications
  • Mina Sefidfard Jahromi

    Substance Abuse Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

    4 shared publications
  • Mohammadjavad Alishahi

    Shiraz University of Medical Sciences

    4 shared publications
  • Charles Dackis

    Treatment Research Center, Department of Psychiatry, School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania

    3 shared publications

Latest Publications

  • Open Access

    The association between hematological markers of inflammation and chronic cannabis use: a systematic review and meta-analysis of observational studies

    by Reza Moshfeghinia, Amirhossein Najibi, Mehrnaz Moradi, Kasra Assadian, Jamshid Ahmadi

    Introduction: Cannabinoids, both natural and synthetic, are a subject of scientific interest. Cannabis is widely used, and its impact on health and the immune system is being studied. The endocannabinoid system influences inflammation, including the Neutrophil-to-Lymphocyte Ratio (NLR), a potential diagnostic tool. Our study investigates the connection between cannabis use and NLR.Methods: Our systematic review was registered in Prospero (#CRD42023463539). We searched six databases (PubMed, Scopus, Embase, PsycINFO, Web of Science, and CINAHL Complete) for records in English from inception to May 2024. We included observational studies that measured the Neutrophil-to-Lymphocyte Ratio (NLR) in cannabis users and control participants. We used the Newcastle–Ottawa Quality Assessment Scale to assess the quality of the included studies. We selected a random-effects model, and the statistical analysis was performed using Stata software version 17.Results: Out of a total of 4,054 records, only five articles were selected for inclusion in the meta-analysis. All of these chosen studies utilized a retrospective design. Furthermore, it's worth noting that all of the studies included were of high quality. In five studies involving 3,359 cannabis users and 10,437 non-users, no significant difference in NLR was found (WMD: 0.12 [-0.16, 0.41], I2: 39.89%). Subgroup analysis on healthy and schizophrenia participants didn't show significant NLR differences (p=0.76). Secondary analysis revealed cannabis users had higher Platelet-to-Lymphocyte Ratio (PLR) (67.80 [44.54, 91.06]), neutrophil count (0.68 [0.25, 1.12]), white blood cell count (0.92 [0.43, 1.41]), monocyte count (0.11 [0.05, 0.16]), and Systemic Immune Inflammation Index (SII) (83.48 [5.92, 157.04]) compared to non-usersConclusion: Our systematic review and meta-analysis reveal that cannabis use may affect NLR and hematologic parameters, suggesting a potential immune impact. Complex associations exist, requiring further research. Schizophrenia and pro-inflammatory factors are discussed, highlighting the need for ongoing investigation into cannabis-related immune changes and mental health.Systematic review registration: https://www.crd.york.ac.uk/prospero/, identifier CRD42023463539.


  • Open Access

    Recurrent cannabis-induced catatonia: a case report and comprehensive systematic literature review

    by Reza Moshfeghinia, Mehrnaz Hosseinzadeh, Sara Mostafavi, Roxana Jabbarinejad, Mahdi Malekpour, Elnaz Chohedri, Jamshid Ahmadi

    Background: Catatonia presents itself as a complex neuropsychiatric syndrome, giving rise to various motor, speech, and behavioral challenges. It is noteworthy that approximately 10% of psychiatric hospital admissions can be attributed to this condition. It is imperative to note that cannabis-induced catatonia, while infrequent, has been linked to the use of marijuana. This connection has the potential to disrupt neurotransmitter systems, necessitating further research for a comprehensive understanding and effective treatment, particularly given the evolving trends in cannabis use. In this context, we shall delve into a unique case of recurrent cannabis-induced catatonia.Case presentation: A 23-year-old gentleman, who has previously struggled with substance use disorder, experienced the emergence of mutism, social isolation, and a fixed gaze subsequent to his use of cannabis. Remarkably, despite the absence of hallucinations, he exhibited recurrent episodes of catatonia. These episodes were effectively addressed through a combination of electroconvulsive therapy (ECT) and lorazepam administration. Notably, when the lorazepam dosage was gradually reduced to below 2 mg per day, the catatonic symptoms resurfaced; however, they promptly abated upon reinstating the medication. The diagnosis of cannabis-induced catatonia was established, and its management primarily involved a therapeutic approach encompassing ECT and lorazepam. It is pertinent to underscore that this catatonic condition can be directly linked to the individual’s cannabis usage.Conclusion: The connection between cannabis and catatonia is intricate and not entirely comprehended. Although cannabis possesses therapeutic advantages, it can paradoxically trigger catatonia in certain individuals. Multiple factors, such as genetics, cannabinoids, and neurotransmitter systems, contribute to this intricacy, underscoring the necessity for additional research.


  • Open Access

    Early onset frontotemporal dementia following cannabis abuse: a case report

    by Reza Moshfeghinia, Bahare Oji, Mehrnaz Hosseinzadeh, Mohammad Pourfridoni, Jamshid Ahmadi

    Background: Frontotemporal disorders (FTD) are the consequence of impairment to neurons in the frontal and temporal lobes of the brain. Also, no definitive treatment has been found for FTD. Cannabinoid products can be used to manage treatment-resistant behavioral variants of Frontotemporal dementia (bvFTD).Case presentation: We describe the case of 34 years old male with two years of marijuana abuse. At first, he presented with symptoms of apathy and bizarre behavior, which became more severe, and led to disinhibition. The clinical symptoms and imaging findings made FTD probable for him, which was very interesting to report.Conclusions: While cannabis has demonstrated potential in managing behavioral and mental symptoms of dementia, the presented case highlights the profound impact of cannabis consumption on brain structure and chemistry, including the potential for neurodegenerative disorders like FTD.


  • Open Access

    Investigating the sequential patterns of methamphetamine use initiation in Iran

    by Ebrahim Moghimi Sarani, Jamshid Ahmadi, Bahare Oji, Motahareh Mahi-Birjand, Nader Bagheri, Amir Bazrafshan, Marie Dehghan Manshadi, Sajad Yaghoubi, Asiyeh Dezhkam, Mehrdad Khatami, et al.

    Background: Methamphetamine (MA) remains one of the most commonly used amphetamine-type stimulants, accounting for the second most widely-used substance after marijuana. Due to increased use of MA, a wide variety of research has focused on the patterns of MA use initiation among adolescents. Nevertheless, there are few data available for people who use MA. The present study set out to assess the sequential patterns of substance use initiation in patients with MA use disorders in Iran. Materials and methods: This cross-sectional study described substance initiation patterns for 302 patients who used MA admitted to hospitals and psychiatric centers of Shiraz University of Medical Sciences. The study was conducted between April 2015 and June 2016. After obtaining informed consents, participants were interviewed by trained interviewers using face-to-face, semi-structured interviews. The collecting data were analyzed using the chi square tests and one-way analysis of variance (ANOVA) tests to compare the relationship between qualitative and quantitative variables, respectively. Results: Out of 302 participants enrolled in the study, 16 (5.3%) and 286 (94.7%) were female and male, respectively. The mean age of participants in the study was 37.29 years. The mean age of onset of MA use was found to be 15.9 years. 46.1% of the patients started MA use before 15 years. 77.2% of the patients who used MA had family members with a history of substance use. 93.71% of the patients who used MA started substance use with tobacco, alcohol, or opium, as the most frequent substances. Tobacco, as the first substance or starting substance, exhibited the most widely-used substance (69.53% of the cases). Tobacco-alcohol-cannabis-opium-heroin-MA sequencing was significantly related to the early onset of the substance use. Early-onset substance use was significantly higher in those with lower income, primary education, and family history of substance use. No significant relationship was found between employment status with the age of onset of substance use, and different substance use with marital status. Conclusion: Tobacco, alcohol and opium can be considered as the main sequencing substances for initiation to MA use. Standardized measures to decrease and control access to main starting and sequencing substances, including tobacco, alcohol, and opium, can greatly help decrease the early onset of the MA use, develop suitable prevention, and establish early intervention strategies.


  • Open Access

    Rapid effect of a single-dose buprenorphine on reduction of opioid craving and suicidal ideation: A randomized, double blind, placebo-controlled study

    by Jamshid Ahmadi, EbrahimMoghimi Sarani, MinaSefidfard Jahromi

    J Indian Prosthodont Soc, Official publication of Indian Prosthodontic Society


  • Prevalence of Substance Abuse (Tobacco, Alcohol, Narcotics and Psychotropic Drugs) and Its Relationship to Family Factors in Pre-university Male Students in Shiraz 2017–2018

    by Ghazanfar Rafiee, Jamshid Ahmadi, Farkhondeh Rafiee

    Teenagers are valuable resources in communities and they are faced with multiple risk factors. Factors such as family attachment, devotion to family, parent’s educational level, and parental support are the protective factors against high-risk behaviors. The purpose of this study was to determine the prevalence of drug use among pre-university students and its relationship with familial factors. 1000 Fourth grade high-school male students were randomly selected during 6 months in four districts of Shiraz City during 2017–2018. 14% of the participants were current smokers, 13.5% had a history of alcohol consumption, and 1% used psychotropic drugs, respectively. Moreover 59% of the participants who had consumed alcohol were cigarette smokers as well. 4.5% of them used all the three substances such as alcohol, tobacco and psychotropic drugs. Children whose parents do not set clear regulations or do not control their children are at higher risk of drug abuse.


  • Open Access

    A randomized clinical trial on the effects of bupropion and buprenorphine on the reduction of methamphetamine craving

    by Jamshid Ahmadi, Ali Sahraian, Mehdi Biuseh

    The purpose of this study was to compare the effect of 300 mg of bupropion and 8 mg of buprenorphine per day on the treatment of methamphetamine withdrawal cravings over a 2-week treatment interval. Sixty-five methamphetamine-dependent men who met the DSM-IV-TR (Diagnostic and Statistical Manual of Mental Disorders, 4th edition, text revision) criteria for methamphetamine dependence and withdrawal were randomly divided into two groups. Subjects randomly received 300 mg of bupropion or 8 mg of buprenorphine per day in a psychiatric ward. Of the 65 subjects, 35 (53.8%) received buprenorphine and 30 (46.2%) received bupropion. The subjects were assessed by using methamphetamine craving score, interview, and negative urine drug test. There were no statistically significant differences between the two groups in regard to age, education, duration of methamphetamine dependency, marital status, employment, and income. The mean ages were 32.8 years (standard deviation (SD) = 7.26, range = 22 to 59) for the buprenorphine group and 32.21 years (SD = 8.45, range = 17 to 51) for the bupropion group. All 65 patients completed the 2-week study. Both medications were effective in the reduction of methamphetamine cravings. Reduction of craving in the buprenorphine group was significantly more than the bupropion group (P = 0.011). Overall, a significant main effect of day (P 0.05) were detected. The results support the safety and effectiveness of buprenorphine and bupropion in the treatment of methamphetamine withdrawal craving. Administration of 8 mg of buprenorphine per day can be recommended for the treatment of methamphetamine withdrawal cravings. We should note that it is to be expected that craving decreases over time without any medication. So the conclusion may not be that bupropion and buprenorphine both lower the craving. As the buprenorphine is superior to bupropion, only buprenorphine does so for sure. Iranian Registry of Clinical Trials (IRCT) registration number: IRCT2015010320540N1 . Date registered: April 10, 2015.


  • Open Access

    The Effect of Single High-dose Buprenorphine on Opioid Craving and Relapse

    by Jamshid Ahmadi, Mina SefidfardJahromi, Dara Ghahremani, Edythe D. London

    Background: Buprenorphine, a treatment for Opioid Use Disorder, has liability for diversion and abuse. Use of single high doses of buprenorphine that are supervised avoid issues with diversion that occur with unsupervised or take home doses. Such doses have the potential to act as an initial opioid detox, facilitate transition to opioid antagonists or drug free treatments, as well as to maintenance treatment. Objective: To assess effects of a single, physician-administered high dose of buprenorphine on craving and on early relapse. Method: Sixty men who used heroin, opium or prescription opioids and met DSM-5 criteria for Opioid Use Disorder received a single, sublingual dose of buprenorphine (32 mg, 64 mg or 96 mg; n’s = 20, 21, and 19) as inpatients on a psychiatric unit. Buprenorphine was administered when patients were in moderate opioid withdrawal (4-5 symptoms). Self-reports of craving were taken at baseline and daily for the next 13 days, and relapse was assessed 1 and 2 months. Findings: Craving was reduced from baseline in each of the three groups (p < 0.0005), but the doseXtime interaction did not reach statistical significance (p= 0.069). Follow-up assessments at 1- and 2-months indicated significantly lower relapse rates for the higher-dose groups than for the low-dose group (p < 0.05). Conclusions: A single high dose of buprenorphine provides rapid relief of opioid craving and positively impacts relapse rate in the initial 1- and 2-months of outpatient treatment. Further investigation of single high-dose buprenorphine for early treatment of patients with Opioid Use Disorder is warranted as an alternative when buprenorphine/naloxone or long-acting buprenorphine dosage forms are not available.

  • Open Access

    The Effect of Single High-dose Buprenorphine on Opioid Craving and Relapse

    by Jamshid Ahmadi, Mina SefidfardJahromi, Dara Ghahremani, Edythe D. London

    Background: Buprenorphine, a treatment for Opioid Use Disorder, has liability for diversion and abuse. Use of single high doses of buprenorphine that are supervised avoid issues with diversion that occur with unsupervised or take home doses. Such doses have the potential to act as an initial opioid detox, facilitate transition to opioid antagonists or drug free treatments, as well as to maintenance treatment. Objective: To assess effects of a single, physician-administered high dose of buprenorphine on craving and on early relapse. Method: Sixty men who used heroin, opium or prescription opioids and met DSM-5 criteria for Opioid Use Disorder received a single, sublingual dose of buprenorphine (32 mg, 64 mg or 96 mg; n’s = 20, 21, and 19) as inpatients on a psychiatric unit. Buprenorphine was administered when patients were in moderate opioid withdrawal (4-5 symptoms). Self-reports of craving were taken at baseline and daily for the next 13 days, and relapse was assessed 1 and 2 months. Findings: Craving was reduced from baseline in each of the three groups (p < 0.0005), but the doseXtime interaction did not reach statistical significance (p= 0.069). Follow-up assessments at 1- and 2-months indicated significantly lower relapse rates for the higher-dose groups than for the low-dose group (p < 0.05). Conclusions: A single high dose of buprenorphine provides rapid relief of opioid craving and positively impacts relapse rate in the initial 1- and 2-months of outpatient treatment. Further investigation of single high-dose buprenorphine for early treatment of patients with Opioid Use Disorder is warranted as an alternative when buprenorphine/naloxone or long-acting buprenorphine dosage forms are not available. Keywords: Buprenorphine; opioid dependence; opioid withdrawal; craving

  • Open Access

    Single high-dose buprenorphine for opioid craving during withdrawal

    by Jamshid Ahmadi, Mina Sefidfard Jahromi, Dara Ghahremani, Edythe D. London

    Opioid use disorder is one of the most prevalent addiction problems worldwide. Buprenorphine is used as a medication to treat this disorder, but in countries where buprenorphine is unavailable in combination with naloxone, diversion can be a problem if the medication is given outside a hospital setting. The objective of this research is to evaluate the effect of a single, high dose of buprenorphine on craving in opioid-dependent patients over 5 days of abstinence from use of other opioids. The primary goal was to determine the safety and efficacy of buprenorphine during withdrawal in a hospital setting. Ninety men who used opium, heroin, or prescribed opioids and met DSM-5 criteria for opioid use disorder (severe form) were randomized to three groups (n = 30 per group) to receive a single, sublingual dose of buprenorphine (32, 64, or 96 mg). The study was conducted in an inpatient psychiatric ward, with appropriate precautions and monitoring of respiratory and cardiovascular measures. Buprenorphine was administered when the patients were in moderate opiate withdrawal, as indicated by the presence of four to five symptoms. A structured clinical interview was conducted, and urine toxicology testing was performed at baseline. Self-reports of craving were obtained at baseline and on each of the 5 days after buprenorphine administration. Craving decreased from baseline in each of the three groups (p < 0.0001), with a significant interaction between group and time (p < 0.038), indicating that groups with higher doses of buprenorphine had greater reduction. A single, high dose of buprenorphine can reduce craving during opioid withdrawal; additional studies with follow-up are warranted to evaluate safety.